流感疫苗接种:投资心血管健康的关键一招
文章结合COVID-19大流行背景,指出呼吸道病毒感染与心脏损伤及心血管风险升高相关。NHLBI资助的INVESTED试验在5200例高危心血管患者中比较高剂量与标准剂量流感疫苗,未发现两种策略在减少心肺事件和死亡方面存在差异。作者综合随机对照试验和观察性数据,认为流感疫苗风险获益良好、成本低且可及,应继续作为心血管风险控制的核心措施,并指出该策略应用不足。
要点
- INVESTED试验显示高剂量与标准剂量流感疫苗在高危心血管人群中无差异。
- 随机对照试验和观察性数据支持高危心血管病患者接种流感疫苗。
- 流感疫苗风险获益良好、成本低,应作为心血管风险控制核心措施。
核心结论
- 流感疫苗接种应继续作为心血管风险控制的核心措施之一。
- 尽管INVESTED试验未显示高剂量优于标准剂量,但疫苗在高危心血管患者中的整体获益仍受随机对照试验和观察性数据支持。
研究设计与样本
- INVESTED试验为NHLBI资助的5200例高危心血管患者比较有效性研究,比较高剂量与标准剂量流感疫苗对心肺事件和死亡的影响。
- 文章为结合随机对照试验与观察性数据的综述性评论。
主要发现
- INVESTED试验发现高剂量与标准剂量流感疫苗策略在高危心血管人群中无差异。
- 急性流感病毒感染与心血管风险升高相关。
- COVID-19大流行期间保持物理距离、洗手和戴口罩等感染控制措施已与全球流感爆发发生率显著下降相关。
关键数值与推荐
- INVESTED试验纳入5200例高危心血管患者,比较高剂量与标准剂量流感疫苗。
- 随机对照试验和观察性数据支持高危心血管病患者接种流感疫苗。
临床怎么用
- 在高危心血管病患者中继续推荐年度流感疫苗接种。
- 将流感疫苗接种与物理距离、洗手、戴口罩等感染控制措施结合。
- 关注并改善流感疫苗在心血管高危人群中的应用不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The link between viral respiratory infection and non-pulmonary organ-specific injury, including cardiac injury, has become increasingly appreciated during the current coronavirus disease 2019 (COVID-19) pandemic. Even prior to the pandemic, however, the association between acute infection with influenza and elevated cardiovascular risk was evident. The recently published results of the NHLBI-funded INfluenza Vaccine to Effectively Stop CardioThoracic Events and Decompensated (INVESTED) trial, a 5200 patient comparative effectiveness study of high-dose vs. standard-dose influenza vaccine to reduce cardiopulmonary events and mortality in a high-risk cardiovascular population, found no difference between strategies. However, the broader implications of influenza vaccine as a strategy to reduce morbidity in high-risk patients remain extremely important, with randomized controlled trial and observational data supporting vaccination in high-risk patients with cardiovascular disease. Given a favourable risk-benefit profile and widespread availability at generally low cost, we contend that influenza vaccination should remain a centrepiece of cardiovascular risk mitigation and describe the broader context of underutilization of this strategy. Few therapeutics in medicine offer seasonal efficacy from a single administration with generally mild, transient side effects, and exceedingly low rates of serious adverse effects. Infection control measures such as physical distancing, hand washing, and the use of masks during the COVID-19 pandemic have already been associated with substantially curtailed incidence of influenza outbreaks across the globe. Appending annual influenza vaccination to these measures represents an important public health and moral imperative.
引用
- Bhatt AS, Vardeny O, Udell JA, et al. Influenza vaccination: a 'shot' at INVESTing in cardiovascular health. Eur Heart J. 2021. PMID: 33748833. doi:10.1093/eurheartj/ehab133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。